Press Release

Sysmex Group Formulates New Long-Term Management Goals

Celebrating Our 50th Anniversary by Taking on New Challenges to Move to the Next Stage

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has formulated new long-term management goals for the period ending March 31, 2026. In line with these goals and in preparation for further technical innovations in the healthcare domain, Sysmex will achieve continued Group growth by creating new testing and diagnostic value, and strengthening the management foundations that support this growth.

In developed countries, ballooning healthcare costs are leading to calls for increased healthcare efficiency. Meanwhile, against a backdrop of economic development, demand is growing in emerging markets to put quality healthcare infrastructures in place. Accordingly, the global healthcare market is expected to continue growing. At the same time, artificial intelligence (AI), big data analytics and other leading-edge technologies are being applied in the healthcare domain. We also see other opportunities for further growth, in such areas as personalized medicine—including genomic medicine that incorporates advances in molecular diagnostic technologies1—and regenerative medicine.

In its aim of being a “Unique & Global Healthcare Testing Company,” Sysmex has created a global sales and service network and expanded its product lineup, centering on the IVD2 domain. We have also sought to be an early provider of advanced services and support leveraging the Internet of Things (IoT), sustaining growth by continuing to create unique solutions.

Taking its 50th anniversary as a milestone, Sysmex has formulated new long-term management goals for the period ending March 31, 2026, with the aim of achieving ongoing growth of the Sysmex Group and reinforcing the management foundation to support this growth. We have also established our long-term vision as a “Unique & Advanced Healthcare Testing Company” and our positioning based on this vision.

Based on our new long-term management goals, we will achieve further growth by strengthening and expanding our core business portfolios, comprising the hematology, urinalysis, hemostasis and immunochemistry fields. In the primary care domain, involving early diagnosis at locations near patients, we will create new services that take advantage of diagnostic techniques accumulated through IVD and IT.

In addition, we will create new diagnostic technologies that contribute to personalized medicine through the fusion of our proprietary technologies and new technologies achieved through open innovation. We also aim to transform our business structure by monetizing businesses centered on the life science field.

Furthermore, we will recruit and foster the human resources essential to supporting the future expansion of our business activities and achieving the Group’s strategic goals. At the same time, with the aim of being a company that enjoys the ongoing support of diverse stakeholders, we will contribute to society through environmental consideration throughout the product life cycle and through activities in our facilities, and by creating new diagnostic value through our business activities. We will also engage in initiatives to reinforce our management foundation, including in the areas of corporate governance and risk management.

By leveraging the technologies and business expertise we have cultivated to date in the IVD domain, we will take advantage of leading-edge technologies to create new diagnostic technologies and continue to take on new challenges. In this manner, Sysmex will achieve a positioning based on its long-term vision as a “Unique & Advanced Healthcare Testing Company,” continuing to contribute to the advancement and development of healthcare. 

Long-Term Management Goals for the Sysmex Group

  (1) Long-term vision toward 2025
    A “Unique & Advanced Healthcare Testing Company”
  (2) Positioning

Creating Innovative Diagnostic Value as a Global Top-Five Company in IVD
We aim to become a global top-five company in IVD by expanding our share of the IVD market, which continues to grow globally, achieving ongoing growth in our core businesses (hematology, urinalysis, hemostasis and immunochemistry) by creating new diagnostic value.
    2)  A Leading Company in Personalized Diagnostics for Optimizing Medical Treatment
Through the fusion of our measurement platforms for genes, cells and proteins and new technologies and knowledge acquired through open innovation, we will create new testing and diagnostic value that provides important keys to the selection of treatment methods, and advance the global realization of personalized medicine.
    3)  A Solution Provider Contributing to the Advancement of Primary Care Diagnostics
By leveraging the diagnostic technologies and IT we have cultivated in the IVD domain, we will provide doctors, nurses, laboratory technologists and other healthcare professionals the solutions they need for early diagnoses at locations near patients, thereby enhancing access to healthcare.
    4)  An Attractive Company Providing Value and Instilling Confidence
Through a distinctive business model, creative technologies, dynamic human resources and sound and advanced corporate management, we aim to remain a company that provides social value and is supported by diverse stakeholders.
    5)  One Sysmex Carrying out High-Speed Management
By providing attractive workplaces where diverse human resources can exercise their talents, we will make use of sophisticated teamwork throughout the Group to achieve efficient and high-speed management. 



Molecular diagnostic technologies:
Technologies for identifying diseases by studying the proteins, DNA, RNA, and other molecules contained in tissues and body fluids.

In vitro diagnostics (IVD):
In general, IVD refers to the testing of blood, urine and other samples to determine physical condition.
Here, IVD refers to the domain of laboratory testing in which IVD is performed.
  • Information contained in the press release is current as of the date of the announcement,
    but may be subject to change without prior notice.

Back to "Press Release"